|
Post by mnkdmorelong on Jan 11, 2016 10:41:20 GMT -5
I am stunned from the Desisto withdrawal of this morning. Why announce a CEO appointment if an important contingency is not waived?
Very significant is that Al Mann was not re-appointed as CEO. He may be too feeble to take on the tasks that lie ahead.
I can't see an 8 figure deal being done to save MNKD as an operating entity. This leaves selling off the assets: Afrezza, TS and the buildings. From the selling price, the first $200 mln go to bondholders. The rest go to us longs. The speculation is the sale price. Given that today's price is up, the market thinks equity will get more than $0.67 /ps.
My guess, and it is a pure guess is $2.00 ps.
|
|
|
Post by rvc on Jan 11, 2016 10:47:33 GMT -5
I would be thrilled with 2 bucks a share, but my guess is Al takes it private for about a buck a share-then he can sell off the assets himself
|
|
|
Post by mindovermatter on Jan 11, 2016 11:04:17 GMT -5
I would be thrilled with 2 bucks a share, but my guess is Al takes it private for about a buck a share-then he can sell off the assets himself While that is a scenario, I don't think he'll do that. He has a lot of people close to him and employees invested in Mannkind and I think he'll want to extract as much as he can for them. If anything, he sells the company for a lot less than he had hoped so those people can at least make something. The biggest disappointment has to be for diabetics who will most likely never be able to experience what Afrezza can do for them and for those who already know how wonderful it is. But at the end of the day, good management that makes sound business decisions matter. Mannkind didn't have that. Unless Al can find a buyer to continue Afrezza, he will have severely faltered with Mannkind and that is what people will unfortunately remember him by.
|
|
|
Post by rch51 on Jan 11, 2016 11:16:11 GMT -5
I am stunned from the Desisto withdrawal of this morning. Why announce a CEO appointment if an important contingency is not waived? Very significant is that Al Mann was not re-appointed as CEO. He may be too feeble to take on the tasks that lie ahead. I can't see an 8 figure deal being done to save MNKD as an operating entity. This leaves selling off the assets: Afrezza, TS and the buildings. From the selling price, the first $200 mln go to bondholders. The rest go to us longs. The speculation is the sale price. Given that today's price is up, the market thinks equity will get more than $0.67 /ps. My guess, and it is a pure guess is $2.00 ps. I strongly believe BK is off the table. They have enough cash to shop assets and even entertain competitive bidding. TS is very valuable. Afrezza is likewise valuable if handled properly. Inventory and factory are also valuable. It does not need to be a fire sale. There's enough cash on hand to take their time and do it right. If you are in under $4.50 I think you're likely to come out of this at or close to whole. Well... that's my hope.
|
|
|
Post by bradleysbest on Jan 11, 2016 11:17:57 GMT -5
At what minimum price would a sale make the shorts hurt?
|
|
|
Post by mnkdorbust on Jan 11, 2016 11:24:01 GMT -5
At what minimum price would a sale make the shorts hurt? I don't think the shorts are hurting. It's us that are hurting. Some of this stuff you can't even make up. Frustrating to say the least.
|
|
|
Post by alethea on Jan 11, 2016 11:27:21 GMT -5
At what minimum price would a sale make the shorts hurt? It's too late. You can not make the shorts hurt. They have already won. I guesstimate Shorts have extracted way, way over a billion dollars already. Perhaps two billion or even more. Who do you think got all the money from selling all the calls? Remember when the market cap used to be nearly four billion? They can probably cover at 3 or 4 dollars per share and still come out WAY ahead. Wow. It's hard to believe.
|
|
|
Post by afrizzle on Jan 11, 2016 11:29:48 GMT -5
I wouldn't jump to conclusions on valuation, let's just wait until we have the next new CEO next week and see what he or she says
|
|
|
Post by alethea on Jan 11, 2016 11:32:06 GMT -5
I wouldn't jump to conclusions on valuation, let's just wait until we have the next new CEO next week and see what he or she says I don't understand. We got the new CEO. It's Matt.
|
|
|
Post by kbrion77 on Jan 11, 2016 11:32:59 GMT -5
Didn't Al sell corporate property in CA that netted $100MM? Has anything been done with that since sale?
|
|
|
Post by kc on Jan 11, 2016 11:43:46 GMT -5
I am stunned from the Desisto withdrawal of this morning. Why announce a CEO appointment if an important contingency is not waived? Very significant is that Al Mann was not re-appointed as CEO. He may be too feeble to take on the tasks that lie ahead. I can't see an 8 figure deal being done to save MNKD as an operating entity. This leaves selling off the assets: Afrezza, TS and the buildings. From the selling price, the first $200 mln go to bondholders. The rest go to us longs. The speculation is the sale price. Given that today's price is up, the market thinks equity will get more than $0.67 /ps. My guess, and it is a pure guess is $2.00 ps. My guess is about 4-5 Billion. The potential is there for a blockbuster if the company markets Afrezza properly. The new owner will do that and it it will be an company like Teva or another company that does not have an strong traditional injectable insulin product.
|
|
|
Post by suebeeee1 on Jan 11, 2016 11:47:02 GMT -5
Didn't Al sell corporate property in CA that netted $100MM? Has anything been done with that since sale? I assume the property the corporation inhabited in CA belonged to Al or the foundation. It wouldn't be MNKDs money.
|
|
|
Post by peppy on Jan 11, 2016 11:54:42 GMT -5
I am stunned from the Desisto withdrawal of this morning. Why announce a CEO appointment if an important contingency is not waived? Very significant is that Al Mann was not re-appointed as CEO. He may be too feeble to take on the tasks that lie ahead. I can't see an 8 figure deal being done to save MNKD as an operating entity. This leaves selling off the assets: Afrezza, TS and the buildings. From the selling price, the first $200 mln go to bondholders. The rest go to us longs. The speculation is the sale price. Given that today's price is up, the market thinks equity will get more than $0.67 /ps. My guess, and it is a pure guess is $2.00 ps. My guess is about 4-5 Billion. The potential is there for a blockbuster if the company markets Afrezza properly. The new owner will do that and it it will be an company like Teva or another company that does not have an strong traditional injectable insulin product. Teva would be the problem solve in every regard. Generic, affordable afrezza, and teva would have TS. Sold.
|
|
|
Post by kball on Jan 11, 2016 11:55:48 GMT -5
Bankruptcy more likely i would think
|
|
|
Post by 4allthemarbles on Jan 11, 2016 12:06:31 GMT -5
BK wouldn't need to happen for at least 2 quarters, maybe 3 without influx. That said, a Buyout ends this nightmare for everyone and may save the products, just not MNKD.
I would love a knight to show up and save the day, but to be honest, that's asking for a lot. But whenever we go to hope, someone else is in control.
|
|